Shilpa Medicare partners with Orion for Recombinant Human Albumin for European market
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Investment demonstrates confidence in America’s commitment to science and innovation
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Subscribe To Our Newsletter & Stay Updated